Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
20 hedge funds and large institutions have $1.29M invested in Aridis Pharmaceuticals Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
18% more funds holding
Funds holding: 17 → 20 (+3)
7.22% less ownership
Funds ownership: 18.66% → 11.44% (-7.2%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
72% less capital invested
Capital invested by funds: $4.58M → $1.29M (-$3.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.55M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$51.5K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$27.3K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$26.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.44M |
| 2 |
BlackRock
New York
|
-$9.19K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.84K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.62K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1.43K |
ARDS Hedge Fund Activity: Q1 2023 in Review
20 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2023, worth a combined $1.29M — down 72% from $4.58M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARDS positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.55M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.44M sold.
- 20 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2023, up from 17 in Q4 2022.
- Funds reported $1.29M of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2023, down 72% quarter-over-quarter.
- 6 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2023 and 3 closed out, a net change of +3 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2023 was Sabby Management, an estimated $1.55M added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2023.